Ruti Aga: Marathon Runner Gets Six-Year Ban for Fake Prescription — How a Knee Injury Became a Career-Ending Conspiracy

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The case is not about doping but about a forged medical prescription issued by a family member. Aga, 32, who won the 2026 Tokyo Marathon and finished second at three World Marathon Majors, is now effectively out of the 2028 Olympic cycle. The ban is backdated to 10 September, the date of her provisional suspension. By the time six years pass, she will be around 38, and given the depth of Ethiopian women's marathon running, a return is practically impossible. Technically, the case involves methylprednisolone, a glucocorticoid that several media reports mislabeled as a "steroid." Under the WADA Prohibited List, it falls under class S9 and is prohibited only in-competition, via injection or oral routes. Its out-of-competition use for a knee injury is entirely legal. Aga's case hinged on this distinction — and it was also the only path to her defence. Aga tested positive after winning a half marathon in China in March. According to the AIU, she cited a knee injury as the reason for treatment, but the prescription submitted was issued by a clinic that did not exist. The "doctor" who signed it was a family member with no medical registration. He claimed to have used an "old prescription pad from a former workplace," but the clinic explicitly disowned the claim. Three independent verification failures. The sanction arithmetic is straightforward: two years for the presence violation and four years for tampering. Six years total. This structure indicates the panel did not accept the "no significant fault" mitigation that could otherwise have reduced the presence sanction. In other words, Aga destroyed her own defence. Had she possessed genuine medical records and a properly documented route and timing of injection, the case might have been shorter — or not have existed at all. Instead, the forgery turned a potentially light sanction into a career-ender. The depth of Ethiopian women's marathon running is such that removing a 2:18–2:20 athlete has no measurable impact on national team capacity. Aga's three Major podium finishes were commercial-tier results, not championship conversions. But that is not the story. The story is why a runner caught between chronic knee pathology, appearance-fee pressure, and cheap glucocorticoid injections had no formal medical support system. A pattern is emerging in AIU East African road-racing cases: an initial substance violation, followed by a fabricated explanation, then a tampering charge. This suggests the enforcement frontier has shifted from "detection" to "document verification." China's label-race circuit, with its large appearance-fee budgets and deep East African elite fields, is now a high-scrutiny zone. Aga's 2026 Tokyo title will remain on her record, as the violation is anchored to a later date. But commercially, she is now radioactive. Sponsorship in distance running is already thin. The question is whether the AIU investigation will reach the agent or management, or remain limited to the family member who signed the prescription. Until that is clear, this case will remain an example of a systemic medical-governance failure rather than a lone individual error.